Innovent Announces $189 Million Agreement for TKI from Hangzhou Company

Suzhou Innovent Biologics acquired China rights to co-develop and commercialize taletrectinib, an AnHeart oncology treatment, in a $189 million deal. Taletrectinib as a next-gen TKI that targets ROS1 and NTRK. AnHeart, a Hangzhou company, is already conducting two Phase II trials of  taletrectinib in China , one in NSCLC and the other in solid tumors, plus a global Phase II trial in NSCLC. Patients with ROS1 and NTRK positive NSCLC acquire resistance to existing treatments. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //